Nachrichten und Videos - BIOTECHNOLOGY

This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further the continuation of the program and the development of new YKL-40 inhibitors. The Bio-dollar value of the...

dBio Partners with Japan's Tamana City to Lead the Future of Smart Healthcare Solutions PR Newswire TAIPEI, Sept. 10, 2024 TAIPEI , Sept. 10, 2024 /PRNewswire/ -- Decentralized Biotechnology Intelligence Co., Ltd (dBio), a global leader in exercise and health platform solutions, has announced a significant milestone in its international expansion. In a strategic move to address Japan's pressing demographic challenges, dBio has signed a Memorandum of Understanding (MOU) with the government of...

CALGARY, AB / ACCESSWIRE / August 22, 2024 / ASIA GREEN BIOTECHNOLOGY CORP. (CSE: ASIA) (" Asia Green " or the " Company ") is pleased to announce that it has entered into a non-binding letter of intent (" LOI ") dated August 22, 2024 to acquire all of the issued and outstanding common shares of Paladin Services Group Ltd. (" Paladin "), a private company that owns a Class II Disposal Well in the Bonnie Glen field area of central Alberta and which has secured disposal commitments from several...

CALGARY, AB / ACCESSWIRE / August 21, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announced today that it has elected to the terminate the previously announced agreement dated February 9, 2024, pursuant to which the Company was to acquire all of the issued and outstanding shares in two private companies being Burton Growers Ltd. and Green-Sight Agri-Holdings Inc. Management of Asia Green has cited delays in obtaining regulatory approval and the ongoing impact of other...

NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. Event: Q3 Investor Summit Date: August 20 th , 2024 Presentation Time: 2:00 pm ET Location: https://www.webcaster4.com/Webcast/Page/3062/51117 The theme...

Company to participate in a fireside chat on Monday, August 5 th at 8:00 AM ET ISELIN, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics will participate in a fireside chat at the BTIG Virtual...

J.P. Morgan Life Sciences Private Capital Closes Inaugural Biotechnology Venture Capital Fund with over $500 million in Commitments PR Newswire NEW YORK, June 13, 2024 NEW YORK , June 13, 2024 /PRNewswire/ -- J.P. Morgan Private Capital, a venture capital and growth equity investment team within J.P. Morgan Asset Management, today announced the final close of the first Life Sciences Private Capital offering, 270 Life Sciences Private Capital Fund I (the "Fund") , led by Chief Investment Officer...

[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES] CALGARY, AB / ACCESSWIRE / May 24, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024, April 26, 2024, May 8, 2024, and May 10, 2024, the Company has filed the following continuous disclosure documents (collectively, the "Documents") on SEDAR: the Company's Annual Audited Financial Statements for the year ended December...

Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector PR Newswire MIAMI, May 15, 2024 MIAMI , May 15, 2024 /PRNewswire/ -- 4Cable TV International, Inc. soon to be known as Category V Biotech, Inc. (OTC: CATV) announced today the execution of a Letter of Intent (LOI) to acquire Genetic Networks, LLC ( https://geneticnetworks.com/ ), a leader in applied molecular biology and drug development. Effective May 15, 2024 , the LOI signifies...

[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES] CALGARY, AB / ACCESSWIRE / May 10, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the Alberta Securities Commission ("ASC") on May 08, 2024, remains in effect. The MCTO prohibits the CEO and CFO of the Company from trading in the...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, AB / ACCESSWIRE / May 8, 2024 / Asia Green Biotechnology Corp. (" Asia Green " or the " Company ") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024 and April 26, 2024, the Alberta Securities Commission ( "ASC" ) has granted the Company's application for the issuance of a Management Cease Trade Order (" MCTO "). The MCTO prohibits the CEO and CFO of the Company from trading in the...

HTL Biotechnology, leader du marché des biopolymères, rachète à Modern Meadow son collagène recombinant humain pour les applications beauté et biomédicales PR Newswire JAVENÉ, France, 6 mai 2024 JAVENÉ, France , 6 mai 2024 /PRNewswire/ -- HTL Biotechnology renforce sa position de leader mondial de la fabrication et du développement de biopolymères de grade pharmaceutique en faisant l'acquisition de la division beauté et biomédicale de l'américain Modern Meadow ( Nutley, NJ ) et...

[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES] CALGARY, AB / ACCESSWIRE / April 26, 2024 / Asia Green Biotechnology Corp. (" Asia Green " or the " Company ") (CSE:ASIA) announces that it will not meet the filing date of April 29, 2024 (" Filing Date "), as required under National Instrument 51-102, for filing of the following continuous disclosure documents (collectively, the " Documents "): The Company's Annual Audited Financial Statements for the year ended...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, AB / ACCESSWIRE / April 17, 2024 / Asia Green Biotechnology Corp. (" Asia Green " or the " Company ") (CSE:ASIA) announces that it is unlikely to meet the filing date of April 29, 2024 (" Filing Date "), as required under National Instrument 51-102, for filing of the following continuous disclosure documents (collectively, the " Documents "): The Company's Annual Audited Financial Statements for the year...

CALGARY, AB / ACCESSWIRE / April 12, 2024 / Asia Green Biotechnology Corp. ("AGB" or the "Company") (CSE:ASIA), announced today that it has changed its auditor from Paul J. Rozek Professional Corporation, Chartered Professional Accountant (the "Former Auditor") to MNP LLP (the "Successor Auditor"), effective April 5, 2024 (the "Effective Date"). At the request of the Company, the Former Auditor resigned as the auditor of the Company and the Board of Directors of the Company appointed the...

EQS-Media / 08.04.2024 / 11:58 CET/CEST Anbio Biotechnology expandiert auf den europäischen Markt mit seinem Starprodukt AF-100 C, einem bahnbrechenden kompakten Fluoreszenz-Immunoassay-Analysegerät, das die Point-of-Care-Tests revolutionieren soll. Mit über 70 Assays soll der AF-100 C Gesundheitsdienstleistern in der EU helfen, die Patientenversorgung und -prognose zu verbessern. Frankfurt, Deutschland - Anbio Biotechnology (Anbio), ein weltweit führender Anbieter von In-vitro-Diagnostika,...

EQS-Media / 08.04.2024 / 11:58 CET/CEST Anbio Biotechnology is expanding into the European market with its star product AF-100 C, a ground-breaking compact fluorescent immunoassay analyzer, which is to revolutionize point-of-care testing. With over 70 assays, the AF-100 C aims to empower healthcare providers in the EU, enhancing patient care and prognosis. Frankfurt, Germany – In a strategic move to broaden its presence in the European Union, Anbio Biotechnology (Anbio), a global leader in...

Jamie Metzl, one of the world's leading technology and healthcare futurists, is all set to headline at the Global AI Show, taking place at the Grand Hyatt Dubai on April 16 and 17, 2024. DUBAI, Mar 25, 2024 - (ACN Newswire) - The Global AI Show is thrilled to announce Jamie Metzl, esteemed author, technology visionary, and healthcare futurist, as a featured speaker for its upcoming two-day conference. Set to convene thought leaders and industry experts from across the globe, this event promises...

HONG KONG, Mar 18, 2024 - (ACN Newswire) - Essex Bio-Technology Limited ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2023. Financial Performance The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023. During the year under review, the Group achieved a consolidated revenue of approximately HK$1,706.6 million, with an increase of 29.5% as compared to last year,...

CYBER ENVIRO-TECH, INC ACQUIRES STABLEX AND SECURES EXCLUSIVE GLOBAL LICENSES TO INTELLECTUAL PROPERTY RIGHTS FROM KAM BIOTECHNOLOGY LTD. PR Newswire SCOTTSDALE, Ariz., Feb. 27, 2024 SCOTTSDALE, Ariz. , Feb. 27, 2024 /PRNewswire/ -- (OTC Pink: CETI), Cyber Enviro-Tech, Inc. is pleased to announce the acquisition of the patent for Stablex and the geographic expansion of its license rights for seven proprietary intellectual biotechnology compounds of KAM Biotechnology Ltd ("KAM") from the United...